

ANTIBODY/TARGETED-DRUG CONJUGATES 2015

13-15 April 2015, Crowne Plaza Porto, Porto, Portugal

FINAL ORAL PROGRAMME & POSTER PROGRAMME ATDC 2015

SCIENTIFIC ADVISORY PANEL

John A. Flygare (*Genentech Inc, South San Francisco, California, USA*)
Greg Bleck (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)
Victor Goldmacher (*ImmunoGen Inc., Waltham, Massachusetts, USA*)
John Lambert (*ImmunoGen Inc., Waltham, Massachusetts, USA*)
Roger R. Beerli (*NBE-Therapeutics LLC, Basel, Switzerland*)
Christoph Rader (*Scripps Research Institute, Jupiter, Florida, USA*)
Michael Firer (*Ariel University, Ariel, Israel*)
Christoph Mamot (*Kantonsspital Aarau AG, Aarau, Switzerland*)
Alain Beck (*Centre d'Immunologie Pierre Fabre, St Julien-en-Genevois, France*)
Hanspeter Gerber (*Pfizer Worldwide R&D, Pearl River, USA*)
Philip Howard (*Spirogen Ltd, London, UK*)
Aaron K. Sato (*SUTRO Biopharma, South San Francisco, California, USA*)

ATDC 2015 is the sister meeting to the established human antibodies series:

HUMAN ANTIBODIES & HYBRIDOMAS

The 19th conference in this long running series will be held in Lausanne, Switzerland on 28-30 October 2015.
For more details please contact John Herriot at the HAH 2015 Secretariat on jherriot@meetingsmgmt.u-net.com

www.meetingsmanagement.com/hah_2015

Please visit the website to view our current and future meetings programme.



Genentech
A Member of the Roche Group

Pfizer Oncology

Catalent

IMMUNOGEN, INC.

SUTRO
BIOPHARMA

LinXis

NatureGeneTherapy

aldevron

ON drugDELIVERY

NBEtherapeutics

Synthon

MerckSerono **MERCK**

08.30-09.25

Registration

09.25-09.30

Welcome & Opening Remarks

John A Flygare (*Genentech Inc, South San Francisco, California, USA*)

**SESSION 1:
PLENARY SESSION**

Moderator: John A Flygare (*Genentech Inc, South San Francisco, California, USA*)

09.30-10.00

KEYNOTE:

'ADCs using the maytansinoid platform: After Kadcyra, whats next?'

John Lambert (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

10.00-10.30

KEYNOTE:

'Next generation ADCs: Expanding the ADC target space by enabling ADCs against tumors with low target expression'

Peter Park (*Mersana Therapeutics Inc, Cambridge, Massachusetts, USA*)

10.30-11.00

Coffee Break & Poster Set-Up

**SESSION 2:
PLENARY II**

Moderator: Hans-Peter Gerber (*Pfizer Worldwide R&D, Pearl River, New York, USA*)

11.00-11.30

'The development of antibody pyrrolbenzodiazepine conjugates'

Philip Howard (*Spirogen Ltd, London, UK*)

11.30-12.00

'Novel ADC targets/ADC target discovery'

David Tice (*Medimmune Inc., Gaithersburg, Maryland, USA*)

12.00-12.30

'The next generation of antibody conjugates:

Moving beyond cytotoxic payloads'

Greg Bleck (*Catalent Pharma Solutions, Madison, Wisconsin, USA*)

12.30-13.00

'Potent and selective a-Amanitin-antibody conjugates'

Kendall Morrison (*Agensys Inc., Santa Monica, California, USA*)

13.00-14.00

Lunch Break & Posters

**SESSION 3:
CONJUGATION TECHNOLOGIES**

Moderator: Aaron Sato (*Sutro Biopharma Inc., South San Francisco, California, USA*)

14.00-14.30

KEYNOTE:

'Antibody-drug conjugates: An emerging modality for the targeted therapy of liquid and solid tumors'

Hans-Peter Gerber (*Pfizer Worldwide R&D, Pearl River, New York, USA*)

14.30-15.00

'Sortase-mediated generation of site-specifically conjugated next-generation ADCs for treatment of cancer'

Roger R. Beerli, Nikolas Stefan, Tamara Hell, Anna S. Merkel and Ulf Grawunder (*NBE-Therapeutics Ltd, Basel, Switzerland*)

15.00-15.30

'Distinct *in vivo* efficacy and PK outcomes of ADCs conjugated site specifically using SMARTag™ technology'

David Rabuka (*Catalent Pharma Solutions, Catalent Biologics - West (formerly Redwood Bioscience, Emeryville, California USA)*)

15.30-16.00

'Beyond CMO services: New conjugation technologies'

Laurent Ducry (*Lonza AG, Visp, Switzerland*)

16.00-16.30

Tea Break & Posters

**SESSION 4:
ALTERNATIVE STRATEGIES**

Moderator: John Lambert (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

16.30-17.00

'Induction of avidity driven hyper-clustering of DR5 by a novel tetravalent bispecific FAP--DR5 antibody (RG7386) leads to strong anti-tumor efficacy'

Klaus Bosslet (*Roche Diagnostics GmbH, Penzberg, Germany*)

17.00-17.30

'Antibody conjugated nanoparticles – an alternative ADC platform'

Christopher Scott (*Queen's University Belfast, Belfast, Northern Ireland, UK*)

17.30-18.00

'A hybrid antibody-nanocarrier conjugate to expose tumors to "Sentinels" of immunity'

Pirouz Daftarian (*University of Miami, Miami, Florida, USA*)

18.00-18.20

'New tools for developability assessments of ADCs'

Maria Wendt (*Genedata AG, Basel, Switzerland*)

ATDC 2015 Drinks Reception & Posters

**SESSION 5:
CANCER**

Moderator: Philip Howard (*Spirogen Ltd, London, UK*)

09.00-09.30

KEYNOTE:

'Antibody-drug conjugates for the treatment of cancer'

John A Flygare (*Genentech Inc, South San Francisco, California, USA*)

09.30-10.00

'Novel DNA-alkylating agents designed for ADCs'

Victor Goldmacher (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

10.00-10.30

'The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers'

Ruud Ubink, Miranda M.C. van der Lee, Patrick Groothuis, Monique A.J. van der Vleuten, Tanja A. van Achterberg, Eline M. Loosveld, Désirée Damming, Daniëlle C.H. Jacobs, Myrthe Rouwette, David F. Egging, Patrick H. Beusker, Peter Goedings, Gijs F.M. Verheijden, Jacques M. Lemmens, C. Marco Timmers and Wim H.A. Dokter (*Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands*)

10.30-11.00

'Anti-glycan monoclonal antibodies as candidate drug carriers for cancer treatment'

Mireille Vankemmelbeke, Silvana Tivadar, Jia X. Chua, Richard S. McIntosh, Robert Moss, Tina Parsons, Ian Spendlove and Lindy G. Durrant (*University of Nottingham, Nottingham, UK*)

11.00-11.30

Coffee Break & Posters

**SESSION 6:
PEPTIDES/PROTEINS**

Moderator: Michael Firer (*Ariel University, Ariel, Israel*)

11.30-12.00

'Phage-derive peptides for use in cancer and immunological diseases'

Michael Firer (*Ariel University, Ariel, Israel*)

12.00-12.30

'RG7787- A deimmunised cytolytic fusion protein (cFP): A favourable alternative to ADCs'

Klaus Bosslet (*Roche Diagnostics GmbH, Penzberg, Germany*)

12.30-13.00

'Development of novel multifunctional peptide-drugs conjugates for targeted chemotherapy'

Gary Gellerman, Lena Regozin, Boris Redko, Yosi Gilad, Michael Firer and Andrei Bazilevich (*Ariel University, Ariel, Israel*)

13.00-14.00

Lunch Break & Posters

**SESSION 7:
ADC DEVELOPMENT I**

Moderator: Roger R. Beerli (*NBE-Therapeutics LLC, Basel, Switzerland*)

14.00-14.45

'The role of preclinical cancer models in ADC development: From target identification to predicting clinical response rates'

Hans-Peter Gerber (*Pfizer Worldwide R&D, Pearl River, New York, USA*)

14.45-15.15

'Producing better ADCs using ThioBridge™ conjugation'

George Badescu (*Abzena PLC, Cambridge, UK*)

15.15-15.45

'Lx, a versatile, water-soluble, platinum-based ADC linker'

Guus A.M.S. van Dongen, Dennis C.J. Waalboer and J.A. Muns (*VU University Medical Center, Amsterdam, The Netherlands*) and HendrikJan Houthoff and Niels J. Sijbrand (*LinXis Pharmaceuticals, Breda, The Netherlands*)

15.45-16.15

Tea Break & Posters

**SESSION 8:
ADC DEVELOPMENT II**

Moderator: Victor Goldmacher (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

16.15-16.45

'Improvement of the therapeutic index of amanitin-based ADCs'

Andreas Pahl and Jan Anderl (*Heidelberg Pharma GmbH, Ladenburg, Germany*)

16.45-17.15

'The application of site-specific conjugation technology to create novel bispecifics, pegylated biologics and peptide conjugates'

Aaron Sato (*Sutro Biopharma Inc., South San Francisco, California, USA*)

17.15-17.45

'Targeting diseases with armed antibodies and small molecule targeted cytotoxics'

Mattia Matasci and Giulio Casi (*Philogen AG, Otelfingen, Switzerland*)

17.45-18.15

'ADC targets and payload delivery: Do we know how to select good targets?'

John Lambert (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

Free Time for ATDC 2015 Delegates

SESSION 9: ADC DEVELOPMENT III

Moderator: Kendall Morrison (*Agensys Inc., Santa Monica, California, USA*)

09.00-09.30

'Synthetic biology and synthetic chemistry converge for novel antibody-drug conjugates'

Toni Kline, Kevin Yin, Krishna Bajjuri, Xiaofan Li, Alexander Steiner, Erik Zimmerman, Gang Yin, Tyler Heibeck, Venita DeAlmeida and Aaron Sato (*Sutro Biopharma Inc., South San Francisco, California, USA*)

09.30-10.00

'Site-specific conjugation by Transglutaminase improves the therapeutic index of ADC *in vivo*'

Florence Lhospice (*Innate-Pharma SA, Marseille, France*)

10.00-10.30

'Bridge and click' conjugation strategies: A new paradigm for the synthesis of porphyrin antibody-drug conjugates'

F. Bryden, A. Maruani, H. Savoie, V. Chudasama, M.E.B. Smith, S. Caddick and R.W. Boyle (*University of Hull, Hull, UK*)

10.30-11.00

Coffee Break & Posters

POSTERS

Poster 101

'Assays for the selection and functional characterization of antibody drug conjugates at the National Research Council of Canada (NRCC)'

Maria Luz Jaramillo, Myriam Banville, Luc Meury, Normand Jolicoeur and Maureen O'Connor-McCourt (*Human Health Therapeutics, NRC of Canada, Montreal, Quebec, Canada*)

Poster 102

'Preparation of antibody recognizing heteromers of dopamine D2 and serotonin 5-HT1A receptors using phage display technology'

Sylvia Lukaszewicz, Ewa Blasiak, Agata Stachowicz, Ewelina Fic and Marta Dziedzicka-Wasylewska (*Jagiellonian University, Krakow, Poland*)

Poster 103

'Development and biological evaluation of photosensitizer-anti-HER2 conjugates for targeted photodynamic therapy of gastric cancer'

Barbara Korsak, Rudolf J. Schneider, Bruno Sarmento, Carla Oliveira and João P. C. Tomé (*University of Aveiro, Aveiro, Portugal*)

Poster 104

'Multiple loading of drugs improves the activity of their targeted peptide conjugates'

Y. Gilad, E. Noy, H. Senderowitz, A. Albeck, M.A. Firer MA and G. Gellerman (*Ariel University, Ariel, Israel*)

Poster 105

'Computational, drug release and biological evaluation of three new anti-cancer cyclic RGD peptide conjugates'

Y. Gilad, E. Noy, H. Senderowitz, A. Albeck, M.A. Firer MA and G. Gellerman (*Ariel University, Ariel, Israel*)

Poster 106

'"Switch off/switch on" regulation of drug cytotoxicity by conjugation to a cell targeting peptide'

Y. Gilad, M.A.Firer, A. Rozovsky, E. Ragozin, B. Redko, A. Albeck and G. Gellerman (*Ariel University, Ariel, Israel*)

Poster 107

'Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar'

Zhongyu Zhu, Ramakrishnan Boopathy, Jinyu Li, Ponraj Prabakaran, Simona Colantonio, Yang Feng, Yanping wang, Marzena A. Dyba and Dimitar S. Dimitrov (*National Cancer Institute, NIH, Bethesda, Maryland, USA*)

Poster 108

'New platform for antibody developability and manufacturability assessment'

Christoph Freiberg¹, Christopher Smith², Sebastian Schlicker², Willem Westra³, Maria Wendt¹ and Hans Peter Fischer¹
(*1 Genedata AG, Basel, Switzerland; 2 Genedata Inc., Boston, Massachusetts, USA; 3 Genedata Inc., San Francisco, California, USA*)

Poster 109

'An integrated system for the design and evaluation of antibody drug conjugates'

Andreas Kaufmann¹, Maria Wendt¹, Peter Ernst¹, Christopher Smith², Carl Bruder¹, Guido Cappuccilli¹ and Hans Peter Fischer¹ (*1 Genedata AG, Basel, Switzerland; 2 Genedata Inc., Boston, Massachusetts, USA*)

Poster 110

'Synthesis, drug release and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety'

B. Redko, A. Albeck, M. Firer and G. Gellerman (*Ariel University, Ariel, Israel*)

SESSION 10: ADC DISCOVERY, EVALUATION & DEVELOPMENT

Moderator: Greg Bleck (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)

11.00-11.30

'Site restricted conjugation: The LinXis ADC alternative for native mAbs: The best of two worlds'

HendrikJan Houthoff, Guus van Dongen, Gerro van Rheenen, Paul Steverink, Joey Muns, Niels Sijbrandi and Dennis Waalboer (*LinXis Pharmaceuticals, Breda The Netherlands*)

11.30-12.00

'High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction'

Victor Goldmacher (*ImmunoGen Inc, Waltham, Massachusetts, USA*)

12.00-12.30

'A new biomarker to enhance the therapeutic index of Amanitin-based ADCs'

Andreas Pahl, Jan Anderl and Xiongbin Lu (*Heidelberg Pharma GmbH, Ladenburg, Germany*)

12.30-13.00

'New workflow system for the design and evaluation of antibody drug conjugates (ADCs)'

Andreas Kaufmann (*Genedata, Basel, Switzerland*)

13.00-14.00

Lunch Break, Poster Breakdown & Departure

* This final programme is correct at the time of printing, however the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.